药物动力学和剂量的建议Niaspan (R)在慢性肾脏疾病和透析病人。
文章的细节
-
引用
复制到剪贴板 -
Reiche我,韦氏比重,Martens-Lobenhoffer J,曲格列酮U, Luley C, Bode-Boger SM
药物动力学和剂量的建议Niaspan (R)在慢性肾脏疾病和透析病人。
Nephrol拨移植。2011年1月,26 (1):276 - 82。doi: 10.1093 /无损检测/ gfq344。Epub 2010年6月17日。
- PubMed ID
-
20562093 (在PubMed]
- 文摘
-
背景:Niaspan (R)是一种延长释放制定烟酸与提高耐受性较速释和缓释配方。它是用来治疗hypertriglyceridaemia较低的高密度脂蛋白水平。这种类型的dyslipidaemia频繁出现在慢性肾脏疾病(CKD)患者。剂量的建议这些病人没有因为药代动力学数据丢失。本研究进行的药物动力学分析prolonged-release烟酸在CKD和透析病人获得剂量的建议。方法:10透析患者和8 CKD患者参与了一项前瞻性,三、非盲药代动力学研究。他们收到500毫克Niaspan第一周每天(R),第二周第三周1000毫克/天,1500毫克/天。在每个处理单元的第四天,11日血浆样本收集24 h post-dose和分析烟酸(NA)及其代谢物烟酰胺和nicotinuric酸(NUA)。结果:与CKD受试者的平均血浆钠浓度明显高于在透析病人,但不高于报道没有肾功能损害的患者。NA的t (max)平均0.75 h在透析患者和3.0 h CKD患者和,因此,尤其是对透析患者,明显短于预期延长释放配方。 It is particularly noticeable that the AUC, C(max) and t(1/2) of the metabolite NUA are significantly higher in dialysis patients in comparison to CKD patients. This may indicate that the dialysis was not effective in removing this metabolite. However, there was no correlation between the incidence of flush and the concentration of NUA. Another possibility could be a drug-drug interaction with omeprazole via CYP450 enzymes. CONCLUSIONS: These data suggest that no dose adjustment of Niaspan(R) is necessary in patients with renal impairment. Despite an extended-release formulation of NA, we could not detect a delay in t(max) especially in dialysis patients. We found no correlation between the incidence of flush and the NUA concentration. Furthermore, there were hints of an interaction with omeprazole.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物